CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 72,600 shares, an increase of 112.3% from the October 15th total of 34,200 shares. Approximately 1.4% of the shares of the company are short sold. Based on an average trading volume of 52,900 shares, the short-interest ratio is presently 1.4 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a research note on Thursday.

Insider Activity at CalciMedica

In related news, CEO A. Rachel Leheny bought 20,000 shares of the stock in a transaction dated Friday, November 1st. The stock was bought at an average cost of $3.75 per share, with a total value of $75,000.00. Following the completion of the acquisition, the chief executive officer now owns 130,926 shares of the company’s stock, valued at $490,972.50. This trade represents a 18.03 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Sanderling Venture Partners Vi purchased 86,867 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average cost of $3.75 per share, for a total transaction of $325,751.25. Following the acquisition, the insider now owns 814,300 shares in the company, valued at approximately $3,053,625. The trade was a 11.94 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 312,944 shares of company stock valued at $1,172,910. Corporate insiders own 41.55% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CalciMedica stock. Atria Investments Inc raised its stake in shares of CalciMedica, Inc. (NASDAQ:CALC) by 136.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,503 shares of the company’s stock after buying an additional 15,296 shares during the period. Atria Investments Inc owned approximately 0.25% of CalciMedica worth $117,000 as of its most recent SEC filing.

CalciMedica Stock Performance

Shares of CALC traded down $0.04 during mid-day trading on Friday, reaching $3.33. 69,828 shares of the company’s stock traded hands, compared to its average volume of 36,805. The business’s 50-day moving average price is $4.04 and its 200-day moving average price is $4.54. The stock has a market capitalization of $35.80 million, a P/E ratio of -3.08 and a beta of 1.30. CalciMedica has a 12 month low of $2.68 and a 12 month high of $8.38.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03. Equities research analysts anticipate that CalciMedica will post -2.21 EPS for the current year.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.